FUNCTIONAL ANALYSIS OF AGERATUM CONYZOIDES L. (BABANDOTAN) LEAVES EXTRACT ON RHEUMATOID ARTHRITIS MODEL RAT

ERNAR FANIAI1, RIRI NURUL SUCI1, KATRIN BASAI1, ADE ARSIANTI2, ANTON BAHTIAR1*
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Indonesia. 2Department of Medicinal Chemistry, Faculty of Medicine, Universitas Indonesia, Kampus UI Salemba, Jakarta, Indonesia. Email: anton.bahtiar@gmail.com

Received: 01 December 2016, Revised and Accepted: 26 December 2016

ABSTRACT

Objective: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation in joints. Ageratum conyzoides L. (Babandotan) leaves are proven to be used in inflammation therapy, yet there is a little data regarding the effects of the leaves on RA. The aim of this study is to investigate anti-RA activity of the ethanolic extract of A. conyzoides L. leaves (EEAL) harvested from Bogor, Indonesia, in rats.

Methods: The phytochemical screening analysis and thin-layer chromatography were performed to analyze the constituents of the EEAL. This study used white male Sprague Dawley rats which were divided into 6 groups: normal control and negative control groups, both given 0.5% carboxymethyl cellulose; the positive control group, given methotrexate suspension (0.05 mg/200 g bw); the dose variation extract is 40 mg, 80 mg, and 160 mg/200 g body weight. All the groups were induced with 0.1 ml Complete Freund’s adjuvant on day 1, except normal control group. Some parameters will be measured, such as paw edema, levels of leukocyte and lymphocyte, concentrations of tumor necrosis factor-α (TNF-α), and the number of osteoclasts per mm².

Results: For 21 days the rats have given treated the EEAL in three doses, was showed the decreasing volume of paw edema, levels of blood leukocytes and lymphocytes, concentrations of TNF-α and the number of osteoclasts, compared to the rat model of RA.

Conclusion: This study showed that the leaves of A. conyzoides L. harvested from Bogor, Indonesia, have activity as anti-RA in a rat model, in which flavonoid plays a role in inhibition of chronic inflammatory processes.

Keywords: Ageratum conyzoides L. leaves, Anti-rheumatoid arthritis, Complete Freud’s adjuvant, Flavonoids.
**Drug and chemicals**

The chemicals used in the study is 70% ethanol solution (Bratco Chemistry, Indonesia), distilled water (Bratco Chemistry, Indonesia), neutral saline 0.9% (Otsuka, Indonesia), m ethotrexate (Ebewe Pharma, Austria), Complete Freund's adjuvant (CFA) containing Mycobacterium tuberculosis (Sigma-Aldrich, USA), and ketamine (Hameln, Germany).

**Animal**

The animal test uses Sprague Dawley rats which obtained from the IPB husbandry, Bogor. The weight of rats is between 175 and 250 g. The rats were randomly divided into 6 groups with each group consist of five rats. The group is conditioned in a cage under standard laboratory conditions, with a light cycle 12 h light on/12 h light off (dark), temperature 22°C-25°C, humidity 40-60%, the rats get access to food water freely, and do tags as identity. Acclimation is performed for 7 days and during the time conducted routine observations concerning the general condition and body weight. This research has certified by ethical certification of Faculty of Medicine, University of Indonesia (UI FK No. 75/UN2.F1/Ethics/2016) for the use of animals in experiments.

**Characterization of extract and chromatographic analysis**

The organoleptic examination results of the extract are has a greenish black color, specifically a Bambahandoran color and slightly bitter taste. The results of non-specific parameter of the EEAL are moisture content was 9%, total ash content was 0.97%, acid insoluble ash content was 0.04%, and the levels of the solvent residue was negative (test using GC). Phytochemical screening observation found that the EEAL containing some chemical metabolites such as flavonoids (produce a red color due to the addition of Zn and Mg, and formed yellow bluish fluorescence using ultraviolet light 366 nm), tannins (white deposits by giving gelatin and gelatin+NAC), alkaloids (light yellow precipitate formed by providing reagents Mayer's, blackish brown color by giving reagent bouchardat), terpenoids steroids (bluish green color), and saponins (froth-formed with a diameter of 1.5 cm). Total flavonoid was 2.31% by spectrophotometry. Thin-layer chromatography used silica plates F254 as the stationary phase for chromatographic characterization of the extract. A total of 10 mg extract was weight and dissolved with 10 ml of ethanol. And the mobile phase used toulene:Ethyl acetate/Formic acid as a ratio of 50:33:9, as well as equal with quercetin.

**Induction of arthritis with CFA**

A total of 30 rats (Sprague Dawley) were induced by CFA [1 mg/ml; 0.1 ml] and were injected in the left hind paw subcutaneously on the 1st day and given a 4-week waiting period to form a rat model of RA [17], except for the normal control group. The rats were divided into 6 groups (I-VI). Each group consist of five rats, i.e., Group I (normal control) and Group II (negative control) applied carboxymethyl cellulose 0.5%, Group III (positive control) applied methotrexate 0.05 mg/200 g bw/d and Groups IV, V, and VI applied the EEAL in three different doses (40, 80, and 160 mg/200 g bw/d) during 21-day period. At day 29, rats were measured for paw edema volume, and level of leukocytes and lymphocytes. At day 50, rats were also measured for paw edema volume, the level of leukocytes and lymphocytes, and then measured for TNF-α concentration, and subsequently, rats were killed to evaluate the number of osteoclast at calcaneus bone.

**Measurement of blood leukocytes and lymphocytes levels**

Blood samples were collected from retro-orbital plexus on day 29 and 50, mixed with ethylenediaminetraacetic acid (EDTA) to prevent coagulation of blood and then measured with a hematology analyzer. Results of blood leukocyte and lymphocyte levels were recorded and analyzed.

**Measurement of TNF-α concentration**

Blood samples were collected from retro-orbital plexus on day 50, (without mixing with EDTA) and then measured with a hematology analyzer. The blood sample was stored at room temperature for 30 min and then centrifuged at 3,000 rpm for 10 min. The resulting serum was collected and stored at −20°C. The content of the cytokine TNF-α concentration was measured using enzyme-linked immunosorbent assay (ELISA) kit by applying optical density absorbance wavelenges of 450 nm and in accordance with manufacturer's procedures. ELISA reader shows the results and further data were analyzed.

**Measurement of number of osteoclasts**

In the previous study, we found that RA made bone resorption in the heel joint especially calcaneus bone [18]. Hence, we evaluated calcaneus bone by calculating osteoclast number on that bone. On the day 50, the rats were set up to performed surgery to isolate the joints (region tibiotarsal) longitudinally midline [19]. The histopathology of calcaneus bone was made by fixation, decalcification, dehydration, purification, and infiltration/embedding in paraffin blocks, and cutting (3-5 µm), finally stained by hematoxylin-eosin staining (H&E). A number of osteoclasts at calcaneus bone were observed using a microscope (×400). Osteoclasts are calculated based on the total number of osteoclasts per measuring area (mm²) (Total No/1Tar) and data were analyzed [20].

**RESULTS**

**Phytochemical screening and chromatographic characterization**

Preliminary phytochemical screening revealed the presence of chemical metabolites such as flavonoids, tannins, alkaloids, terpenoids steroids, and saponins. Thin-layer chromatography appearance results showed flavonoids with RF value was 0.53, which almost equivalent to the standard solution, quercetin with RF value was 0.52. It indicated that in the EEAL, there were secondary metabolites such as flavonoids equivalent to quercetin (Fig. 1). The result showed that the EEAL has met to the specification of Indonesian Herbal Pharmacopoeia [21-23].

**Effect on paw edema volume**

Anti-RA activity of the EEAL on rat paw edema induced by CFA (p=5) is shown in Fig. 2a. Paw edema volume was measured by plethysmometer on day 29 and 50. On day 50 shown that the three EEAL doses can be reduced paw edema volume significantly (p<0.05) within 21 days treatment (in Dose I: 1.24; Dose II: 1.22; Dose III: 1.1) compared to edema volume for the negative control group (1.88). Edema inhibitory activity of the EEAL was found 34.04% in Dose I, 35.10% in Dose II, and 41.49% in Dose III on day 50. The edema inhibitory activity was highest in doses of 160 mg/200 g bw/d of the EEAL but lower than positive control, methotrexate (53.19%) (Fig. 2b). Application of the EEAL showed inhibitory activity edema in rats induced by CFA, and also showed the anti-inflammatory effect on chronic inflammation.

**Effect on level of blood leukocytes and lymphocytes**

Anti-RA activity of the EEAL is showed by the levels of blood leukocytes and lymphocytes in Fig. 3. It is shown by observation on day 29 and 50 that the reducing of blood leukocytes levels caused by suppression of the EEAL activity compared to the negative control group; it obtained the results as follows: Dosage I: 13.6 and 13.7; Dosage II: 14.4 and 13.7; Dosage III: 14.2 and 11.5. Moreover, it was showed on day 50, the reducing of blood leukocytes level was significant seen (p<0.05) in the dosage of 160 mg/200 g bw/d of the EEAL compared to negative control groups (14.0 and 16.2) and similar to the positive control group, (methotrexate [15.2 and 11.0]).
reducing of blood lymphocytes level caused by suppression activity of the EEAL compared to the negative control group that observed on day 29 and 50; It showed, i.e.: In Dosage I: 9.0 and 7.8; Dosage II: 9.5 and 6.5; Dosage III: 11.1 and 7.4. There is a significant decrease in the levels of lymphocytes (p<0.05) on the three EEAL dosage variation treatment, compared with negative controls group (10.1 and 11.0). This observation shows similar results when compared to the positive control group (methotrexate [9.6 and 7.3]).

Effect on TNF-α concentration

Effect of anti-RA activity of the EEAL against TNF-α concentration in the rat is shown in Fig. 4. TNF-α concentration suppression activity of the EEAL was analyzed by ELISA kit and was found 274.3 pg/ml in Dosage I, 236 pg/ml in Dosage II, and 244.3 pg/ml in Dosage III on day 50. As shown in the results, concentration of TNF-α group AR rat model increased when compared to normal control group. The concentration of TNF-α was reduced by the administration of three dose levels of the EEAL compared to the negative control group (316 pg/ml) but higher than the positive control group, (methotrexate [232.6 pg/ml]). The EEAL showed inhibitory activity concentrations of TNF-α and it shows the anti-inflammatory effect on chronic inflammation.

Effect on number of osteoclasts

Observation number of osteoclasts in calcaneus bone by histopathology examination in rats induced CFA showed an increased amount compared with the normal control group. This result was a similar result in a previous study [18]. Anti-RA activity of three doses levels of
the EEAL proven to reduce the number of osteoclasts compared to the negative control group. After 21 days of treatment, the results showed the reducing number of osteoclasts was significant seen (p<0.05) in the dosage of 160 mg/200 g bw./d of the EEAL compared to negative control groups. The total number of osteoclasts per mm² in each group at day 50 was as shown in Fig. 5.

**DISCUSSION**

RA is a chronic inflammatory disease associated with the immune system. Inflammation begins with an increased of capillary permeability that allows the inflammatory cells (neutrophils and leukocytes) in the blood vessels to reach into inflammation areas which cause fluid influx. The body will attempt to stop the inflammatory process, but when the attempt went unsuccessful, the process will develop into a chronic inflammation. The chronic inflammation, usually associated with the immune system and which inflammatory cells such as mononuclear cells (lymphocytes and monocytes) will play a dominant role rather than PMN cells. In this study, a rat model induced by CFA containing M. tuberculosis. The CFA-induced arthritis rat model had extensively used as a laboratory model and has been reported successful to create RA rats model [19,24,25]. Rats were induced by CFA in the left hind paw subcutaneously on day 1 and then wait up to 4 weeks, to formed RA rats model [17].

*A. conyzoides* leaves were purchased in Bogor, Indonesia, where local communities traditionally use Babandotan leaves for the treatment of inflammatory disease in their daily live, such as fever, swelling, soreness, stiffness, wound, and abdominal discomfort. From preliminary screening, the result showed that the EEAL was containing various secondary metabolites such as flavonoids, tannins, alkaloids, terpenoids sterol, and saponins. Thin layer chromatography result showed flavonoids was equivalent to quercetin. Flavonoids have the core structure of the C6-C3-C6, two aromatic rings connected by 3 C atoms, typically with O atoms bond which form a heterocyclic enzyme cyclooxygenase and lipooxygenase, inhibition of leukocyte accumulation, inhibition of neutrophil degranulation, histamine release, and inhibition anti-inflammatory activity (such as inhibiting production and activities pro-inflammatory cytokines). Quercetin, a member of flavonoids, has been extensively reviewed on its effects on inflammatory processes [27].

This study showed that the EEAL can inhibit the process of RA significantly in CFA-induced rat paw edema (especially in Dose III; 160 mg/200 g bw.) compared to the negative control group. The previous study by Moura et al., 2005, [4] showed that the hydroalcoholic extract of *A. conyzoides* leaves (250 mg/kg bw.; p.o.) had a 38% (p<0.05) reduction in cotton pellet granuloma and the development of chronically induced paw edema was also reduced significantly (p<0.05) by the plant extract. Paw edema due to acute inflammation allowed the influx of inflammation cells and fluid into the inflamed area. The decrease of TNF-α concentration affects a decreased volume of paw edema, through inhibition of cyclooxygenase. The increased of paw edema inhibition of the EEAL showed that flavonoids had the anti-inflammatory effect through the mechanism of action in inhibiting the activity of inflammatory cells and pro-inflammatory cytokines in CFA-induced rats. The EEAL dose used in the study was according to the previous studies [4] and was explained that hydroalcoholic extract of *A. conyzoides* had low toxicity/LD50 (=5.000 mg/kg, p.o) which make it relatively safe to use [5,28].

On the level of blood leukocytes test result, it is shown that giving the EEAL can reduce the level of blood leukocytes compared to negative control, as well as the blood lymphocytes because the inflammatory process that occurred was inhibited by flavonoids. Recent studies by Diallo et al., 2010, [28] showed flavonoid from the extract of *A. conyzoides* lowered white blood cells (WBC) in treated rats. CFA-induced in rats caused chronic inflammation, which makes the level of blood leukocyte and lymphocyte increased on day 29. The EEAL which contains flavonoids can inhibit the release of pro-inflammation cytokines such as TNF-α which can increase the infiltration of inflammatory cells into the inflamed area, that showed on day 50 [4,29,30].

The treatment by giving the EEAL, which contained quercetin, can decrease the concentration levels of TNF-α compared to negative control. Previous studies by Nair et al. 2005 [27] explained that quercetin in significantly inhibited TNF-α production and down-regulated gene expression in a dose-dependent manner. Anti-inflammation effect of quercetin by PBMCs (peripheral blood of mononuclear cells) which are mediated by inhibition of pro-inflammatory cytokine TNF-α via inhibiting activation of NF-kB, TNF-α is a pro-inflammatory cytokines which have an important role in the inflammatory process, such as increasing adhesion and infiltration of inflammatory cells into the inflamed area, increasing spending of other pro-inflammatory cytokines (such as IL-1, IL-2, and IFN-γ), increasing the occurrence of angiogenesis, thus simplifying the pannus and cause damage to the articular cartilage and bone so that further aggravate the state of RA [27,31].

In parameter on osteoclast counting, giving the EEAL can reduce the number of osteoclasts in calcaneous bone rats compared to negative control. The osteoclast is bone cells that play an important role in the absorption and bone regeneration [32]. Recent studies by Almarestani et al. 2011 [17] explained that induction CFA (1 mg/ml; 0.15 ml) subcutaneously in rats by day 15 showed joint and periartricular swelling with widened joint space at the MTP joints as an early sign of arthritis, and by day 30 showed soft tissue swelling, erosions, joint deformity, periostal new bone formation, and trabecular bone thickness were further reduced. The increase of TNF-α concentration can elevate the amount of RANKL-RANK bond which also increases the production and activity of osteoclast, causing bone erosion that may worsen the RA disease [33-35]. Studies by Stolina et al. (2005) [36] showed that RANKL significantly increased during inflammatory arthritis in rats that associated with bone erosions and RANKL inhibition through OPG prevented local and systemic bone loss in arthritis models. Secondary metabolites such as flavonoids contained in the EEAL can inhibit the production and activity of TNF-α, so there was no excessive increase in the number and activity of osteoclasts.

**CONCLUSION**

The EEAL harvested from Bogor, Indonesia has an activity of anti-RA in rats model, and flavonoids play an important role in inhibiting the progressivity of RA disease. These results also corroborate experimental evidence of traditional usage of *A. conyzoides* L. (Babandotan) leaves by local communities in Bogor, Indonesia in handling various inflammatory diseases, particularly RA.
ACKNOWLEDGMENTS

The authors would like to acknowledge to Ministry of Research Technology and Higher Education of Indonesia for supporting this research.

Graphical abstract

REFERENCES

1. Okunade AL. Ageratum conyzoides L. (Asteraceae). Fitoterapia 2002;73(1):1-16.
2. Kamboj A, Saluja AK. Isolation of stigmasterol and B-sitosterol from petroleum ether extract of aerial parts of Ageratum conyzoides (Asteraceae). JIPPS 2011;3(1):94-6.
3. Singh SB, Devi WR, Marina, Devi WI, Swapana N, Singh CB. Ethnobotany, phytochemistry and pharmacology of Ageratum conyzoides Linn (Asteraceae). J Med Plants Res 2013;7(8):371-85.
4. Moura AC, Silva EL, Fraga MC, Wanderley AG, Afiatpour P, Maia MB. Ageratum conyzoides L., a new anti-inflammatory and chronic toxicity study of the leaves of Ageratum conyzoides L. in rats. Phytomedicine 2005;12(1-2):138-42.
5. Hassain MM, Shahid-ud-Daula AUF, Jahan IA, Nimmi I, Adnan T, Mansur AA, et al. Anti-inflammatory activity, total flavonoid and tannin content from Ethanolic extract of Ageratum conyzoides Linn. Leaf. JIPPR. 2012;15(3):234-41.
6. Nathiaya S, Durga M, Thiyagarajan, D. Quercetin, encapsulated quercetin and its application - A review. JIPPS 2014;6(10):20-6.
7. Amadi BA, Duru MK, Agomo EN. Chemical profiles of leaf, stem, root and flower of Ageratum conyzoides. AJPSR 2012;2(4):428-32.
8. Okoli CO, Akah PA, Nwafor SV. Review, anti-inflammatory activity of plants. J Nat Med 2003;3(1):1-30.
9. Mehta A, Sethiya NK, Mehta C, Shah GB. Anti-arthritis activity of roots of Hemidesmus indicus R.Br. (Anantmul) in rats. Asian Pac J Trop Med 2012;5(2):130-5.
10. Paul S, Das AP, Bhattacharjee. Rheumatoid Arthritis: Molecular basis and mechanisms for rapid quantitative analysis. Vet Pathol 2004;41(5):683-93.
11. Miyamoto T, Suda T. Review: Differentiation and function of osteoclasts. Keio Med J 2002;51(1):1-7.
12. Braun T, Zwerina J. Positive regulation of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther 2011;13(4):235.
13. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: Mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 2010;36(2):385-404.
14. Stolina M, Adamu S, Onminsky M, Dwyer D, Asuncon F, Geng Z, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005;20(10):1756-65.
15. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nature Reviews Rheumatology, 2012;8(11):656-64.
16. Stolina M, Schett G, Dwyer D, von der Recke J, Mittendorf S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies. Arthritis research & therapy. 2009;11(6):1.